Literature DB >> 17085822

Stem cells in cardiovascular disease: methods and protocols.

Marc S Penn1, Niladri Mal.   

Abstract

Stem cells are cells capable of proliferation, self-renewal, and differentiation into various organ-specific cell types. Stem cells are subclassified based on their species of origin (mice, rat, human), developmental stage of the species (embryonic, fetal, or adult), tissue of origin (hematopoietic, mesenchymal, skeletal, neural), and potential to differentiate into one or more specific types of mature cells (totipotent, pluripotent, multipotent). Embryonic stem (ES) cells are totipotent, primitive cells derived from the embryo that have the potential to become all specialized cell types. Conversely, adult stem cells are undifferentiated cells found in differentiated tissue that retain the potential to renew themselves and differentiate to yield organ-specific tissues. Stem cells are attractive candidates for novel therapeutics for patients with different heart diseases, including congestive heart failure, most commonly caused by myocardial infarction. The remarkable proliferative and differentiation capacity of stem cells promises an almost unlimited supply of specific cell types including viable functioning cardiomyocytes to replace the scarred myocardium following transplantation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085822     DOI: 10.1385/1-59745-213-0:329

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  3 in total

1.  Slow turning lateral vessel bioreactor improves embryoid body formation and cardiogenic differentiation of mouse embryonic stem cells.

Authors:  Sasitorn Rungarunlert; Nuttha Klincumhom; Theerawat Tharasanit; Mongkol Techakumphu; Melinda K Pirity; Andras Dinnyes
Journal:  Cell Reprogram       Date:  2013-09-10       Impact factor: 1.987

Review 2.  Molecular imaging is indispensable for the development of stem cell-based myocardial regenerative therapy.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03       Impact factor: 9.236

3.  Functional outcome after anal sphincter injury and treatment with mesenchymal stem cells.

Authors:  Levilester Salcedo; Marc Penn; Margot Damaser; Brian Balog; Massarat Zutshi
Journal:  Stem Cells Transl Med       Date:  2014-05-05       Impact factor: 6.940

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.